- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT06234384
Foundation for Sarcoidosis Research Advanced Cures Registry (FSR-SARC Registry)
September 15, 2025 updated by: Foundation for Sarcoidosis Research
The goal of the study is to create a longitudinal record of patient reported outcomes for people living with sarcoidosis that maintains privacy.
Patients report on the following: demographics, disease symptoms, diagnostic journey, provider experience, disease treatment, and burden of disease.
Patients can also link their Electronic Health Records (EHR).
The goal is to create a natural history of sarcoidosis, support research, and better understand the needs of the sarcoidosis community.
Study Overview
Detailed Description
Participants review a document, Understanding Your Participation, and check boxes on the Participant Informed Consent document that confirms they understand the risks/benefits of participation (or Assent if the patient is a minor age 7-18), they create an online account, and then are asked to complete the baseline survey questionnaire.
Participants confirm they understand that their participation is completely voluntary, that their identifying information will be secured and encrypted, their private health information will be stored separately in a secure database.
Their private information will never be shared with other people, unless its required by law.
The registry may share de-identified information with researchers and other databases.
Their personal information will be protected and not shared.
They may choose to stop their participation at any time by contacting FSR.
They are not required to fill out all the questions and can leave any unanswered.
They will be contacted by the registry once a year to update or correct their health information.
They can choose to be contacted by FSR if a study becomes available that they may wish to know more about.
Study Type
Observational
Enrollment (Estimated)
6833
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Contact
- Name: Leslie Serhuck, MD MA Mbioethics
- Phone Number: 312-341-0500
- Email: info@stopsarcoidosis.org
Study Contact Backup
- Name: Tricha Shivas, MBe
- Phone Number: 312-341-0500
- Email: tricha@stopsarcoidosis.org
Study Locations
-
-
Illinois
-
Chicago, Illinois, United States, 60654
- Recruiting
- Foundation For Sarcoidosis Research
-
Contact:
- Tricha Shivas, MBe
- Phone Number: 312-241-0400
- Email: tricha@stopsarcoidosis.org
-
Contact:
- Rebecca A Epstein, MPH
- Phone Number: 312-340-0500
- Email: rebecca@stopsarcoidosis.org
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
- Child
- Adult
- Older Adult
Accepts Healthy Volunteers
Yes
Sampling Method
Non-Probability Sample
Study Population
Any adult or child (with a parent or legal guardian's assent) who has been given the diagnosis of sarcoidosis (including juvenile sarcoidosis or Blau Syndrome), and who are able to understand the consent form explaining the risks and benefits of participation.
Description
Inclusion Criteria:
- English speaking
- Consent
- Sarcoidosi diagnosis -
Exclusion Criteria:
NONE
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Completed participation in baseline survey
Time Frame: If a survey question is completely blank, a query can be sent to request the subject to complete the section. Subjects will be contacted only twice to attempt to resolve an issue. The timeframe from time to event outcome shall not exceed 6 months.
|
Baseline survey completion
|
If a survey question is completely blank, a query can be sent to request the subject to complete the section. Subjects will be contacted only twice to attempt to resolve an issue. The timeframe from time to event outcome shall not exceed 6 months.
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Actual)
July 1, 2013
Primary Completion (Estimated)
June 1, 2033
Study Completion (Estimated)
July 1, 2033
Study Registration Dates
First Submitted
January 16, 2024
First Submitted That Met QC Criteria
January 29, 2024
First Posted (Actual)
January 31, 2024
Study Record Updates
Last Update Posted (Estimated)
September 19, 2025
Last Update Submitted That Met QC Criteria
September 15, 2025
Last Verified
September 1, 2025
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- Pro00008556
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
NO
IPD Plan Description
All patient data is de-identified, researchers can request access to de-identified data only.
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
No
Studies a U.S. FDA-regulated device product
No
product manufactured in and exported from the U.S.
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Sarcoidosis
-
Mayo ClinicNot yet recruitingCardiac Sarcoidosis | Sarcoidosis, Cardiac | Sarcoidosis With Myocarditis | Sarcoidosis of the HeartUnited States
-
Celularity IncorporatedTerminatedStage 2 Pulmonary Sarcoidosis | Stage 3 Pulmonary SarcoidosisUnited States
-
Vanderbilt UniversityNational Heart, Lung, and Blood Institute (NHLBI)CompletedSarcoidosis; Antimycobacterial TherapyUnited States
-
Duke UniversityFoundation for Sarcoidosis ResearchRecruiting
-
Sanjay Gandhi Postgraduate Institute of Medical...RecruitingSarcoidosis Lung | Pulmonary SarcoidosisIndia
-
Alexandria UniversityCompletedEndobronchial Mucosal Pathology in Pulmonary SarcoidosisEgypt
-
Heart Center Leipzig - University HospitalRecruiting
-
British Columbia Cancer AgencyApproved for marketing
-
University of Maryland, BaltimoreMallinckrodtCompleted
-
University of PennsylvaniaAdvanced Accelerator ApplicationsCompleted
Clinical Trials on Sarcoidosis diagnosis
-
Rennes University HospitalCompletedSarcoidosis, PulmonaryFrance
-
Foundation for Sarcoidosis ResearchCompletedSarcoidosis | Cardiac Sarcoidosis | Boeck's Disease | Besnier-Boeck DiseaseUnited States, United Kingdom, Netherlands
-
Imperial College LondonGenentech, Inc.WithdrawnIdiopathic Pulmonary Fibrosis | Sarcoidosis
-
The Cleveland ClinicNational Institute on Minority Health and Health Disparities (NIMHD); National...RecruitingDepression | Fatigue | Anxiety | Mental Health | SarcoidosisUnited States
-
Medical University of South CarolinaNational Institute for Biomedical Imaging and Bioengineering (NIBIB)CompletedFatigue | SarcoidosisUnited States
-
Griffin HospitalCalifornia Walnut CommissionCompletedMetabolic SyndromeUnited States
-
Sidney Kimmel Comprehensive Cancer Center at Johns...National Cancer Institute (NCI)CompletedBrain and Central Nervous System TumorsUnited States
-
Rajavithi HospitalCompletedHyperparathyroidism | Vitamin D Deficiency | Hypocalcemia | Systemic Lupus Erythematosus (Disorder)Thailand
-
First Affiliated Hospital Xi'an Jiaotong UniversityRecruiting
-
Fondazione Policlinico Universitario Agostino Gemelli...Active, not recruitingA Multi-Dimensional Model of cAre and transItion for Patients With cOmplex RAre Diseases (AD-MAIORA)Mitochondrial Diseases | Muscular Dystrophies | Rare Diseases | Dysmorphic Disorder, BodyItaly